Perimeter Medical Imaging AI Announces Important Milestone in ATLAS AI Project With FDA Investigational Device Exemption (IDE) Approval to Launch Clinical Trial Using Perimeter B-Series OCT With ImgAssist AI in Breast Conservation Surgery

Stock Information for Perimeter Medical Imaging AI Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Perimeter Medical Imaging AI Inc.

Perimeter Medical Imaging AI Announces Webinar Featuring AI Expert, Anantha Kancherla, Discussing Trends in the Use of Machine Learning and Artificial Intelligence in Healthcare Applications
Perimeter Medical Imaging AI Announces Participation at the Upcoming Annual Meeting of the American Society of Breast Surgeons (ASBrS) and Provides Corporate Updates
Perimeter Medical Imaging AI Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Perimeter Medical Imaging AI Provides Corporate Update on Grant Funding Opportunities and Announces Conference Call/Webcast to Discuss Fourth Quarter and Year-End 2023 Financial Results
Perimeter Medical Imaging AI Reports Its Proprietary Artificial Intelligence Algorithm + OCT Identified 96.8% of Positive Breast Cancer Margins in Newly Published Peer Reviewed Study
Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Research Examining the High Rates of Re-Operations Following Breast-Conserving Surgeries and the Associated Increased Healthcare Costs
Perimeter Medical Imaging AI Announces Expanded Commercial Presence within National Healthcare Provider System with Follow-On Placement of Perimeter S-Series OCT at Additional Hospital Site
Perimeter Medical Imaging AI Announces Further Commercial Expansion in North Texas with Follow-On Placement of Perimeter S-Series OCT within National Healthcare Provider System

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.